In the wake of FDA approval for 2 new CAR T-cells based immunotherapies, hopes are high for patients suffering from cancers of the blood. Such a promising start raises the bar for future improvements in this technology:
This webinar monitored by Rob Frederickson will review all these questions and explore the present and possible futures for CAR T cell immunotherapies with experts Pr. Bruce Levine, Dr Marcella Mauss and Dr Michel Sadelain.
Professor in Cancer Gene Therapy
Perelman School of Medicine, University of Pennsylvania
Director, Center for Cell Engineering
Memorial Sloan Kettering Cancer Center
Assistant Professor of Medicine
Harvard Medical School